Indications of Crizotinib

1. ALK- or ROS1-Positive Metastatic Non-Small Cell Lung Cancer

Crizotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.

2. Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma

Crizotinib is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.  Limitations of Use: The safety and efficacy of Crizotinib have not been established in older adults with  relapsed or refractory, systemic ALK-positive ALCL.

3. Unresectable, Recurrent, or Refractory ALK-Positive Inflammatory Myofibroblastic Tumor

Crizotinib is indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.

from FDA，2023.09